Drug-Drug Interaction Study: ASP2151 and Midazolam
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
CYP3A4 is involved in the metabolism of many drugs. So, it is important to assess in vivo the
induction effect of ASP2151 on that enzyme to determine the extent of any possible drug
interactions. The aim of this trial is to investigate the potential for interaction of
ASP2151 with the CYP3A4 probe substrate midazolam.